Iovance Biotherapeutics Narrows Q1 Loss to $0.19, Misses Revenue Estimates

IOVAIOVA•13d ago

Iovance Biotherapeutics posted a Q1 loss of $0.19 per share, narrowing from a $0.36 loss a year ago. Quarterly revenue missed analysts' consensus estimates.

1. Q1 EPS and Loss Comparison

Iovance posted a net loss of $0.19 per share in Q1, narrowed from a $0.36-per-share loss a year earlier. This outcome was in line with analysts' consensus estimates.

2. Revenue Shortfall

Quarterly revenue fell short of analysts' consensus, highlighting challenges in product commercialization. The shortfall underscores the firm's need to accelerate sales momentum to support future growth.

Iovance Biotherapeutics Narrows Q1 Loss to $0.19, Misses Revenue Estimates

1. Q1 EPS and Loss Comparison

2. Revenue Shortfall

Related News

Chip Rally Boosts AMD as Nvidia Forecasts $91B Sales and $80B Buybacks

Google, Blackstone Launch $5B AI Cloud JV with 500MW Capacity by 2027

Enhanced Trial Shifts to Five-Year Monitoring After 91% Athlete Testosterone Use

JPMorgan Predicts Surge in China IPOs While CEO Warns on Rising Rates

Hedge Funds Back Nvidia-Powered AI Data Centers as Shares Fall 1.3% After $80B Buyback

Sources

Ask about IOVA

Iovance Biotherapeutics Narrows Q1 Loss to $0.19, Misses Revenue Estimates

1. Q1 EPS and Loss Comparison

2. Revenue Shortfall

Related News

Chip Rally Boosts AMD as Nvidia Forecasts $91B Sales and $80B Buybacks

Google, Blackstone Launch $5B AI Cloud JV with 500MW Capacity by 2027

Enhanced Trial Shifts to Five-Year Monitoring After 91% Athlete Testosterone Use

JPMorgan Predicts Surge in China IPOs While CEO Warns on Rising Rates

Hedge Funds Back Nvidia-Powered AI Data Centers as Shares Fall 1.3% After $80B Buyback

Sources